DOCSLIB.ORG

Endoscopy in Patients on Antiplatelet Or Anticoagulant Therapy, Including Direct Oral Anticoagulants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Endoscopy in Patients on Antiplatelet Or Anticoagulant Therapy, Including Direct Oral Anticoagulants Downloaded from http://gut.bmj.com/ on February 15, 2016 - Published by group.bmj.com Guidelines Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines Andrew M Veitch,1 Geoffroy Vanbiervliet,2 Anthony H Gershlick,3 Christian Boustiere,4 Trevor P Baglin,5 Lesley-Ann Smith,6 Franco Radaelli,7 Evelyn Knight,8 Ian M Gralnek,9,10 Cesare Hassan,11 Jean-Marc Dumonceau12 For numbered affiliations see ABSTRACT guidelines on the management of acute non- end of article. The risk of endoscopy in patients on antithrombotics variceal upper gastrointestinal bleeding.1 Correspondence to depends on the risks of procedural haemorrhage versus Recommendations for the management of Dr Andrew Veitch, Department thrombosis due to discontinuation of therapy. patients on antiplatelet therapy or anticoagulants of Gastroenterology, New P2Y12 receptor antagonists (clopidogrel, undergoing elective endoscopic procedures are out- Cross Hospital, Wolverhampton prasugrel, ticagrelor) For low-risk endoscopic lined in the algorithms in figures 1 and 2. Risk WV10 0QP, UK; procedures we recommend continuing P2Y12 receptor stratification for endoscopic procedures and anti- [email protected] antagonists as single or dual antiplatelet therapy (low platelet agents (APAs) are detailed in tables 1 and This article is published quality evidence, strong recommendation); For high-risk 2. There is no high-risk category of thrombosis for simultaneously in the journal endoscopic procedures in patients at low thrombotic risk, DOACs as they are not indicated for prosthetic Endoscopy. Copyright 2016 © we recommend discontinuing P2Y12 receptor metal heart valves. Warfarin risk stratification is Georg Thieme Verlag KG antagonists five days before the procedure (moderate detailed in table 3. Our recommendations are based Received 16 November 2015 quality evidence, strong recommendation). In patients on on best estimates of risk:benefit analysis for throm- Revised 30 December 2015 dual antiplatelet therapy, we suggest continuing aspirin bosis versus haemorrhage. When discontinuing Accepted 4 January 2016 (low quality evidence, weak recommendation). For high- antithrombotic therapy, patient preference should risk endoscopic procedures in patients at high thrombotic be considered as well as clinical opinion: the risk of risk, we recommend continuing aspirin and liaising with a potentially catastrophic thrombotic event such as a cardiologist about the risk/benefit of discontinuation of a stroke may not be acceptable to a patient even if P2Y12 receptor antagonists (high quality evidence, that risk is very low. strong recommendation). For all endoscopic procedures we recommend Warfarin The advice for warfarin is fundamentally continuing aspirin (moderate evidence, strong rec- unchanged from British Society of Gastroenterology ommendation), with the exception of endoscopic (BSG) 2008 guidance. submucosal dissection (ESD), large colonic endo- Direct Oral Anticoagulants (DOAC) For low-risk scopic mucosal resection (EMR) (>2 cm), upper endoscopic procedures we suggest omitting the morning gastrointestinal EMR and ampullectomy. In the dose of DOAC on the day of the procedure (very low latter cases, aspirin discontinuation should be con- quality evidence, weak recommendation); For high-risk sidered on an individual patient basis depending endoscopic procedures, we recommend that the last on the risks of thrombosis versus haemorrhage dose of DOAC be taken ≥48 h before the procedure (low quality evidence, weak recommendation). (very low quality evidence, strong recommendation). For patients on dabigatran with CrCl (or estimated glomerular filtration rate, eGFR) of 30–50 mL/min we recommend that the last dose of DOAC be taken 72 h 1.1 Low-risk procedures For low-risk endoscopic procedures we recommend Open Access before the procedure (very low quality evidence, strong Scan to access more continuing P2Y12 receptor antagonists (eg, clopi- free content recommendation). In any patient with rapidly deteriorating renal function a haematologist should be dogrel), as single or dual antiplatelet therapy (low consulted (low quality evidence, strong quality evidence, strong recommendation). recommendation). For low-risk endoscopic procedures we suggest that warfarin therapy should be continued (low quality evidence, weak recommendation). It should be ensured that the International normalised ratio 1.0 SUMMARY OF RECOMMENDATIONS (INR) does not exceed the therapeutic range in the These guidelines refer to patients undergoing elect- week prior to the procedure (low quality evidence, ive endoscopic gastrointestinal procedures. strong recommendation). To cite: Veitch AM, Management of antiplatelet therapy and direct oral For low-risk endoscopic procedures we suggest Vanbiervliet G, Gershlick AH, anticoagulants (DOACs) in acute gastrointestinal omitting the morning dose of DOACs on the day et al. Gut 2016;65: haemorrhage is discussed in detail in European of the procedure (very low quality evidence, weak – 374 389. Society of Gastrointestinal Endoscopy (ESGE) recommendation) 374 Veitch AM, et al. Gut 2016;65:374–389. doi:10.1136/gutjnl-2015-311110 Downloaded from http://gut.bmj.com/ on February 15, 2016 - Published by group.bmj.com Guidelines High Risk Procedure Polypectomy Low Risk Procedure ERCP with sphincterotomy Diagnostic procedures +/- Ampullectomy biopsy EMR/ESD Biliary or pancreatic stenting Dilation of strictures Diagnostic EUS Therapy of varices Device-assisted enteroscopy PEG without polypectomy EUS with FNA Oesophageal, enteral or colonic stenting clopidogrel clopidogrel prasugrel prasugrel ticagrelor ticagrelor Continue therapy Low Risk Condition High Risk Condition Ischaemic heart disease Coronary artery stents without coronary stent Cerbrovascular disease Peripheral vascular disease Liaise with cardiologist Consider stopping clopidogrel, Stop clopidogrel, prasugrel or ticagrelor 5 days prasugrel or ticagrelor before endoscopy if: 5 days before endoscopy >12 months after insertion of Continue aspirin if already drug-eluting coronary stent prescribed >1 month after insertion of bare metal coronary stent Continue aspirin Figure 1 Guidelines for the management of patients on P2Y12 receptor antagonist antiplatelet agents undergoing endoscopic procedures. 1.2 High-risk procedures patients on dual antiplatelet therapy, we suggest continuing For high-risk endoscopic procedures in patients at low throm- aspirin (low quality evidence, weak recommendation). botic risk, we recommend discontinuing P2Y12 receptor For high-risk endoscopic procedures in patients at low throm- antagonists (eg, clopidogrel) five days before the procedure botic risk, we recommend discontinuing warfarin 5 days before (moderate quality evidence, strong recommendation). In the procedure (high quality evidence, strong recommendation). High Risk Procedure Polypectomy ERCP with sphincterotomy Ampullectomy Low Risk Procedure EMR/ESD Diagnostic procedures +/- Dilation of strictures biopsy Therapy of varices Biliary or pancreatic stenting PEG Device-assisted enteroscopy EUS with FNA without polypectomy Oesophageal, enteral or colonic stenting DOAC Warfarin Dabigatran Warfarin DOAC Rivaroxaban Dabigatran Apixaban Rivaroxaban Edoxaban Apixaban Edoxaban Continue Warfarin Low Risk Condition High Risk Condition Check INR during the week Prosthetic metal heart valve in Prosthetic metal heart valve in before endoscopy Omit DOAC on aortic position mitral position If INR within therapeutic range morning of Xenograft heart valve Prosthetic heart valve and AF continue usual daily dose procedure AF without valvular disease AF and mitral stenosis Take last dose of drug If INR above therapeutic range >3months after VTE <3months after VTE > 48 hours before but <5 reduce daily dose until Thrombophilia syndromes (liaise – INR returns to therapeutic with haematologist) procedure range For dabigatran with CrCl (eGFR) 30-50ml/min take last dose of drug 72 hours before procedure Stop warfarin 5 days In any patient with rapidly before endoscopy deteriorating renal function a Stop warfarin 5 days Start LMWH 2 days after stopping haematologist should be consulted before endoscopy warfarin Check INR prior to procedure to Give last dose of LMWH >– 24 ensure INR<1.5 hours before procedure Restart warfarin evening of Restart warfarin evening of procedure with usual daily dose procedure with usual daily dose Check INR 1 week later to Continue LMWH until INR ensure adequate anticoagulation adequate Figure 2 Guidelines for the management of patients on warfarin or direct oral anticoagulants (DOAC) undergoing endoscopic procedures. Veitch AM, et al. Gut 2016;65:374–389. doi:10.1136/gutjnl-2015-311110 375 Downloaded from http://gut.bmj.com/ on February 15, 2016 - Published by group.bmj.com Guidelines Table 1 Risk stratification of endoscopic procedures based on the Table 3 Risk stratification for discontinuation of warfarin therapy risk of haemorrhage with respect to the requirement for heparin bridging High risk Low risk High risk Low risk Endoscopic polypectomy Diagnostic procedures±biopsy Prosthetic metal heart valve in Prosthetic metal heart valve in aortic ERCP with sphincterotomy Biliary or pancreatic stenting mitral position position Sphincterotomy+large balloon papillary Device-assisted enteroscopy Prosthetic heart valve and atrial Xenograft heart valve dilatation without polypectomy fibrillation Ampullectomy
Load more

Recommended publications
  • Italy and Ligurian Regional HTA Network Abstract Number: 169775
    Abstract Number: 169775 Mini HTA: an effective tool for clinical governance, resource allocation and conflict management at local (Regional) level. Gaddo Flego MD, Francesco Cardinale MD, ASL Nr 4 "Chiavarese", Italy and Ligurian Regional HTA Network The Italian National Health System is centrally governed by the Ministry of Health and by Local Health Authorities (ASL) at Regional level. The Region of Liguria is divided into 5 ASL. Each ASL governs hospitals in the territory of competence. Liguria, for the government of technological innovation, approved with a formal act in 2011 (DGR 295) the creation of a Regional HTA Network in order to implement the process of Health Technology Assessment and to develop the concept of Evidence Based Medicine. The main point of the resolution is the introduction of a Mini HTA grid, that must be filled by proponents before the introduction of any technological innovation. Regional HTA Workflow Since 2011 the Ligurian Network Regional HTA Network has Organisation & Role Hospitals require innovative evaluated the following technologies through Mini devices: Director HTA grid compilation 1) Virtual Colonoscopy CAD Coordination group 2) Porcine Dermal Collagen Surgery Consists of all Professionals who Grid submission to Scientific 3) Sling for urinary incontinence may be involved in the Secretariat 4) Collagen Matrix for sutures evaluation, depending on the 5) Fixation device in surgery device to be evaluated: doctors 6) Sterilization devices with different specialisations, Analysis of quality of data 7) Implantable device for Glaucoma clinical engineers, chemists, produced in the grid, 8) Intravascular Catheter context and scientific health economists and 9) Optical Coherence Tomography literature by the Scientific 10) Pneumothorax drainage system representatives of the citizens.
    [Show full text]
  • Enteroliths in a Kock Continent Ileostomy: Case Report and Review of the Literature
    E200 Cases and Techniques Library (CTL) similar symptoms recurred 2 years later. A second ileoscopy showed a narrowed Enteroliths in a Kock continent ileostomy: efferent loop that was dilated by insertion case report and review of the literature of the colonoscope, with successful relief of her symptoms. Chemical analysis of one of the retrieved enteroliths revealed calcium oxalate crystals. Five cases have previously been noted in the literature Fig. 1 Schematic (●" Table 1). representation of a Kock continent The alkaline milieu of succus entericus in ileostomy. the ileum may induce the precipitation of a calcium oxalate concretion; in contrast, the acidic milieu found more proximally in the intestine enhances the solubility of calcium. The gradual precipitation of un- conjugated bile salts, calcium oxalate, and Valve calcium carbonate crystals around a nidus composed of fecal material or undigested Efferent loop fiber can lead to the formation of calcium oxalate calculi over time [5]. Endoscopy_UCTN_Code_CCL_1AD_2AJ Reservoir Competing interests: None Hadi Moattar1, Jakob Begun1,2, Timothy Florin1,2 1 Department of Gastroenterology, Mater Adult Hospital, South Brisbane, Australia The Kock continent ileostomy (KCI) was dure was done to treat ulcerative pan- 2 Mater Research, University of Queens- designed by Nik Kock, who used an intus- colitis complicated by colon cancer. She land, Translational Research Institute, suscepted ileostomy loop to create a nip- had a well-functioning KCI that she had Woolloongabba, Australia ple valve (●" Fig.1) that would not leak catheterized daily for 34 years before she and would allow ileal effluent to be evac- presented with intermittent abdominal uated with a catheter [1].
    [Show full text]
  • Doacs) and the Antidote Idarucizumab
    Update overview 2019 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab Introduction Lareb previously published yearly overviews of reports (most recently in 2018) in consultation with the Medicines Evaluation Board CBG-MEB, concerning the direct oral anticoagulants (DOACs) dabigatran Pradaxa®, registered in the Netherlands in 2008 [1], rivaroxaban Xarelto®, registered in 2008 [2], apixaban Eliquis®, registered in 2011 [3] and edoxaban (Lixiana®), registered in 2015 [4-9]. The current overview provides a new yearly update of the reports received by Lareb for these DOACs. Furthermore, reports received by Lareb for the antidote idarucizumab are described in this overview. Idarucizumab is a specific antidote for dabigatran and was registered in the Netherlands in 2015 [10]. For this overview, data from the national ADR database were used. These data include reports with serious outcome from the Lareb Intensive Monitoring System (LIM). The DOACs have been monitored with the LIM methodology since September 2012. Prescription data The number of patients using DOACs in the Netherlands according to the GIP database is shown in table 1 [11]. These data are based on extramurally provided medication included in the Dutch health insurance package. Because the antidote idarucizumab is administered in the hospital and not reimbursed directly via the healthcare insurance, these data are not available for this drug. The number of reports received by the Netherlands Pharmacovigilance Centre Lareb per year since 2013 for each DOAC, is also shown in table 1. Furthermore, table 1 shows the calculated number of these reports per 1.000 users according to the GIP database. As noted before, the data from the GIP database represent reimbursed medicines and these may differ from actually prescribed medicines.
    [Show full text]
  • Edoxaban Switch Programme - Frequently Asked Questions
    Edoxaban Switch Programme - Frequently Asked Questions What should I tell patients? NHS Tayside is reviewing all patients currently receiving a Direct Oral Anticoagulant (DOAC) for stroke prevention in NV-AF(non-valvular atrial fibrillation) Edoxaban has been identified as the first choice DOAC. It is similarly effective to the other DOAC options but costs considerably less Clinical experts in Tayside are supporting the use of edoxaban All newly diagnosed NV-AF patients will be started on edoxaban as 1st choice for those unsuitable for warfarin Existing patients already on a DOAC for NV-AF are to be reviewed and considered for switch to edoxaban This will help to ensure that the money available to spend on medicines is being used appropriately Is edoxaban as good as the other DOACs? Yes, the evidence is that it is as effective as warfarin and the other DOACs. It is licensed for this indication and has been recommended by the Scottish Medicines Consortium Other Scottish Health Boards are also considering the use of edoxaban A recent Health Improvement Scotland (HIS) summary (http://www.healthcareimprovementscotland.org/our_work/cardiovascular_dis ease/programme_resources/doac_review_report.aspx) is consistent with this Tayside switch recommendation Lead clinicians from cardiology, stroke, vascular medicine, relevant MCN’s and haematology are all supportive of this Tayside guidance on the basis of current evidence Will we need to do a further switch if the price of other DOACs falls? The rebate on edoxaban is in place for five
    [Show full text]
  • Group Supplemental Limited Benefit Insurance Plan 2
    Group Supplemental Limited Benefit Insurance Plan 2 Group Medical BridgeSM* insurance can help with medical costs associated with a hospital stay that your health insurance may not cover. These benefits are available for you, your spouse and eligible dependent children. *The policy name is Group Supplemental Limited Benefit Insurance. Hospital confinement ............................................................... $_______________1,000 per day Maximum of one day per covered person per calendar year Waiver of premium Available after 30 continuous days of a covered confinement of the named insured £ Daily hospital confinement ................................................................... $100 per day Maximum of 365 days per covered person per confinement. Re-confinement for the same or related condition within 90 days of discharge is considered a continuation of a previous confinement. £ Diagnostic procedure .................................................................. $_______________not available per day Maximum of one day per covered person per calendar year £ Outpatient surgical procedure ¾ Tier 1..................................................................................... $_______________500 per day ¾ Tier 2..................................................................................... $_______________1,000 per day Maximum of $________________1,500 per covered person per calendar year for Tier 1 and 2 combined Maximum of one day per outpatient surgical procedure Diagnostic procedures The following is a list
    [Show full text]
  • Use of Esophageal Stents After Anastomotic Leakage in Surgery for Gastric Adenocarcinoma Case Report and Review of the Literature
    ISSN: 2574-1241 Volume 5- Issue 4: 2018 DOI: 10.26717/BJSTR.2018.06.001391 Fernando Mendoza-Moreno. Biomed J Sci & Tech Res Case Report Open Access Use of Esophageal Stents After Anastomotic Leakage in Surgery for Gastric Adenocarcinoma Case Report and Review of the Literature Mendoza-Moreno F*1, Díez-Gago MR2, Mínguez-García J1, Enjuto-Martínez DT1,Tallón-Iglesias B1, Solana-Maoño M1 and Argüello-de-Andrés JM1 1Department of General and Digestive Surgery,Sanitas La Moraleja Teaching Hospital, Spain 2Department of Emergency, Príncipe de Asturias Teaching Hospital, Spain Received: July 4, 2018; Published: July 12, 2018 *Corresponding author: Fernando Mendoza-Moreno, Department of General and Digestive Surgery, Sanitas La Moraleja Teaching Hospital, Madrid, Spain Abstract Introduction: Radical gastrectomy is the treatment of choice for the treatment of gastric cancer located in the upper third of stomach or in case of diffuse histology or cells in a signet ring. The worst complication after a radical gastrectomy is the leakage of the esophago-jejunal anastomosis, since it considerably increases the morbidity and mortality of the patient. Case Report: Wedescribe our experience after performing a radical gastrectomy for gastric adenocarcinoma in a patient who developed a leakage of the esophago-jejunal anastomosis in the postoperative period. Although he was reoperated, performing reinforcement of the anastomosis and making a feeding jejunostomy, the dehiscence progressed in the following days until it became almost complete. Then, we proceeded to place a digestive endoprosthesis through gastroscopy with good results, allowing the entire defect to heal and being able to be removed without incidents after 8 weeks.
    [Show full text]
  • Anatomisch-Therapeutisch-Chemische Klassifikation Mit Tagesdosen Für Den Deutschen Arzneimittelmarkt Gemäß § 73 Abs
    Wissenschaftliches Institut der AOK GKV-Arzneimittelindex Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt gemäß § 73 Abs. 8 Satz 5 SGB V. 14. Sitzung der Arbeitsgruppe ATC/DDD des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen am 27. November 2015, BMG in Berlin © WIdO 2015 GKV-Arzneimittelindex Agenda • Das anatomisch-therapeutisch-chemische Klassifikationssystem • Entwicklung der ATC/DDD Klassifikation • Workflow ATC/DDD 2016 • Beschlussvorlage • Stellungnahmen zu der Beschlussvorlage • Workflow ATC/DDD 2017 © WIdO 2015 14. Sitzung der Arbeitsgruppe ATC/DDD des KKG 2 GKV-Arzneimittelindex Agenda • Das anatomisch-therapeutisch-chemische Klassifikationssystem • Entwicklung der ATC/DDD Klassifikation • Workflow ATC/DDD 2016 • Beschlussvorlage • Stellungnahmen zu der Beschlussvorlage • Workflow ATC/DDD 2017 © WIdO 2015 14. Sitzung der Arbeitsgruppe ATC/DDD des KKG 3 GKV-Arzneimittelindex Das Anatomisch-therapeutisch-chemische Klassifikationssystem A Alimentäres System und Stoffwechsel B Blut und blutbildende Organe C Kardiovaskuläres System D Dermatika G Urogenitalsystem und Sexualhormone H Systemische Hormonpräparate, exkl. Sexualhormone u. Insuline J Antiinfektiva zur systemischen Anwendung L Antineoplastische und immunmodulierende Mittel M Muskel- und Skelettsystem N Nervensystem P Antiparasitäre Mittel, Insektizide und Repellenzien R Respirationstrakt S Sinnesorgane V Varia © WIdO 2015 14. Sitzung der Arbeitsgruppe ATC/DDD des KKG 4 GKV-Arzneimittelindex Das Anatomisch-therapeutisch-chemische
    [Show full text]
  • Stents for the Gastrointestinal Tract and Nutritional Implications
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #46 Carol Rees Parrish, R.D., M.S., Series Editor Stents for the Gastrointestinal Tract and Nutritional Implications Michelle Loch Michel Kahaleh Endoscopic stenting of many sites along the gastrointestinal tract is used successfully for palliation of malignant or benign obstructions. These obstructions may be the result of primary gastrointestinal tumors invading the lumen, tumors of another primary site causing external compression or in some instance benign diseases secondary to various inflammatory processes. Stenting of the gastrointestinal tract has been commonly per- formed either by interventional radiologists with the use of fluoroscopy, or by gas- troenterologists endoscopically, with or without fluoroscopic guidance. Their efficacy can be measured by resolution of obstruction or symptom improvement. The current literature shows that endoscopic stenting have acceptable success and complication rates and might be considered as first-line therapy in centers offering expertise in inter- ventional endoscopy. The techniques, efficacy and complication of stenting will be dis- cussed. Nutritional guidelines will also be provided based on our institutions practice. INTRODUCTION most current literature (Table 1) (4–9). Common causes ndoscopy within the last two decades has encom- of stent requirement to preserve nutritional status passed many interventional procedures allowing include esophageal, duodenal, biliary and colonic Ethe treatment of multiple conditions of the upper obstruction;
    [Show full text]
  • Long-Term Outcomes and Complications of Metallic Stents for Malignant Esophageal Stenoses
    Kobe J. Med. Sci., Vol. 49, No. 6, pp. 133-142, 2003 Long-term Outcomes and Complications of Metallic Stents for Malignant Esophageal Stenoses RYOTA KAWASAKI1, AKIRA SANO2, and SHINICHI MATSUMOTO2 Department of Radiology, Kobe University Graduate School of Medicine, Kobe1, Department of Radiology, Tenri Hospital, Tenri, Nara2 Received 13 January 2004/ Accepted 6 February 2004 Key words: Esophagus; Malignant Stenoses; Ultraflex Stents; Outcomes; Complications Thirty patients with malignant esophageal stenosis underwent Ultraflex esophageal stent deployment and were followed up for a maximum of 29 months from June 1995 to August 2001 in Tenri Hospital. Twelve stents were in the upper esophagus, and nine each in the middle and lower esophagus. The procedures were successful and dysphagia scores improved from 2.9 to 0.7. Major complications such as esophagorespiratory fistula, hematemesis, or airway compression occurred in 9 patients, more often in the upper esophagus than in other parts of the esophagus, with no statistical difference. There was a significant difference in the onset of major complications between the upper and middle esophagus, as well as between the upper and middle-lower esophagus (p<0.05), but no difference in mean survival time between locations, or patients with or without major complications. These results demonstrate that esophageal stent deployment is effective for relieving dysphagia and associating malnutrition. But major complications may occur in the upper esophagus more often and earlier than in other parts. Metallic stents are effective in relieving those patients with malignant esophageal stenosis from their suffering from dysphagia and malnutrition. On the other hand, several serious complications after the stent deployment or during the long-term follow up have been described in the literature, which include massive bleeding, tracheal compression, esophagorespiratory fistula, and esophageal compression1-10).
    [Show full text]
  • Lixiana, INN-Edoxaban
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Lixiana 15 mg film-coated tablets Each 15 mg film-coated tablet contains 15 mg edoxaban (as tosilate). Lixiana 30 mg film-coated tablets Each 30 mg film-coated tablet contains 30 mg edoxaban (as tosilate). Lixiana 60 mg film-coated tablets Each 60 mg film-coated tablet contains 60 mg edoxaban (as tosilate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Lixiana 15 mg film-coated tablets Orange, round-shaped film-coated tablets (6.7 mm diameter) debossed with “DSC L15”. Lixiana 30 mg film-coated tablets Pink, round-shaped film-coated tablets (8.5 mm diameter) debossed with “DSC L30”. Lixiana 60 mg film-coated tablets Yellow, round-shaped film-coated tablets (10.5 mm diameter) debossed with “DSC L60”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Lixiana is indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). Lixiana is indicated in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). 2 4.2 Posology and method of administration Posology Prevention of stroke and systemic embolism The recommended dose is 60 mg edoxaban once daily.
    [Show full text]
  • Laboratory Monitoring of Direct Oral Anticoagulants (Doacs)
    biomedicines Review Laboratory Monitoring of Direct Oral Anticoagulants (DOACs) Claire Dunois HYPHEN BioMed, Sysmex Group, 95000 Neuville sur Oise, France; [email protected] Abstract: The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous anticoagulant therapies. DOACs directly, selectively, and reversibly inhibit factors IIa or Xa. The coagulation effect follows the plasma concentration–time profile of the respective anticoagulant. The short half-life of a DOAC constrains the daily oral intake. Because DOACs have predictable pharmacokinetic and pharmacodynamic responses at a fixed dose, they do not require monitoring. However in specific clinical situations and for particular patient populations, testing may be helpful for patient management. The effect of DOACs on the screening coagulation assays such as prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) is directly linked to reagent composition, and clotting time can be different from reagent to reagent, depending on the DOAC’s reagent sensitivity. Liquid chromatography–mass spectrometry (LC-MS/MS) is considered the gold standard method for DOAC measurement, but it is time consuming and requires expensive equipment. The general consensus for the assessment of a DOAC is clotting or chromogenic assays using specific standard calibrators and controls. This review provides a short summary of DOAC properties and an update on laboratory methods for measuring DOACs. Keywords: DOAC; monitoring; screening assays; quantitative assays Citation: Dunois, C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). 1. Introduction Biomedicines 2021, 9, 445. https:// Direct oral anticoagulants (DOACs) constitute first-line therapy used for many throm- doi.org/10.3390/biomedicines9050445 boembolic indications, such as prevention and treatment of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF) [1,2].
    [Show full text]
  • Tracheoesophageal Fistula(TEF), Tracheostomy, Nasogastric Tube, Esophageal Stent, Trichloroacetic Acid (TCA)
    hf RACI PHAGEAL FISTULA: ON IN MANAGEMENT Surinder K. Singhal,* Ramandeep S.Virk, ** Arjun Dass,*** Biinaljit Singh Sandhu**** Key words: Tracheoesophageal fistula(TEF), Tracheostomy, Nasogastric tube, esophageal stent, trichloroacetic Acid (TCA). INTRODUCTION: & vomiting after taking food. The patient was a known diabetic and hypertensive on regular treatment. She had undergone a Tracheoesophageal fistula (TEF) is a communication between the medical termination of pregnancy and developed a faecal fistula. esophagus and trachea which can be congenital or acquired. She was operated for the fecal fistula and a colostomy was also About 80% of the acquired tracheoesophageal fistulae are done but on the second post operative day she had cardiac malignant and rest non-malignant' . arrest. She was intubated and revived. Later she underwent a Nonmalignant fistulae are usually due to trauma which can be tracheostomy and remained on ventilatory support for two iatrogenic, internal or external. latrogenic fistulae may occur weeks. She was gradually weaned off the ventilator and on 19` 1 following mechanical ventilation or as a complication of day of tracheostomy she was decanulated and discharged. tracheostomy. Internal trauma may be due to cuffed endotracheal She came back after a week with the complaints of violent cough, tube or nasogastric tubes or a combination of both. It may be regurgitation and vomiting after meals. Systemic examination external trauma from penetrating foreign bodies, open or closed was within normal limits. Colostomy bag was in situ. Local aero digestive tract injuries' .There are many risk factors examination revealed a tracheostomy scar. Oral cavity and associated with post intubation tracheoesophageal fistula like Oropharynx were unremarkable.
    [Show full text]